JP4542336B2 - ベンゼン環上にアミノ基を有するβ−ベンジルオキシアスパラギン酸誘導体 - Google Patents
ベンゼン環上にアミノ基を有するβ−ベンジルオキシアスパラギン酸誘導体 Download PDFInfo
- Publication number
- JP4542336B2 JP4542336B2 JP2003507101A JP2003507101A JP4542336B2 JP 4542336 B2 JP4542336 B2 JP 4542336B2 JP 2003507101 A JP2003507101 A JP 2003507101A JP 2003507101 A JP2003507101 A JP 2003507101A JP 4542336 B2 JP4542336 B2 JP 4542336B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- formula
- threo
- tboa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title claims description 11
- 125000003277 amino group Chemical group 0.000 title description 8
- 239000002253 acid Substances 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 68
- -1 n-butanoyl group Chemical group 0.000 claims description 53
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 24
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 239000003446 ligand Substances 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 125000002252 acyl group Chemical group 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- 108010078791 Carrier Proteins Proteins 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 229930195714 L-glutamate Natural products 0.000 claims description 8
- 125000004057 biotinyl group Chemical class [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims description 8
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 7
- 125000001931 aliphatic group Chemical group 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 claims description 3
- 108090001008 Avidin Proteins 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 239000012312 sodium hydride Substances 0.000 claims description 3
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 claims description 2
- 125000001980 alanyl group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 claims description 2
- 125000002711 cysteinyl group Chemical group 0.000 claims description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 claims description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 5
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims 4
- 229940024606 amino acid Drugs 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- FUMLKAFCVQJVEZ-UHFFFAOYSA-N [bromo(nitro)methyl]benzene Chemical compound [O-][N+](=O)C(Br)C1=CC=CC=C1 FUMLKAFCVQJVEZ-UHFFFAOYSA-N 0.000 claims 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 claims 1
- 229910001863 barium hydroxide Inorganic materials 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 229960002989 glutamic acid Drugs 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 239000000243 solution Substances 0.000 description 44
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 40
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 26
- 235000003704 aspartic acid Nutrition 0.000 description 26
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- 239000012044 organic layer Substances 0.000 description 25
- 239000002904 solvent Substances 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 20
- 235000019341 magnesium sulphate Nutrition 0.000 description 20
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- 238000005481 NMR spectroscopy Methods 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 108091006151 Glutamate transporters Proteins 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 102000034575 Glutamate transporters Human genes 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000000605 extraction Methods 0.000 description 13
- 229930195712 glutamate Natural products 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 230000003197 catalytic effect Effects 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- BYOBCYXURWDEDS-IUCAKERBSA-N (2s,3s)-2-amino-3-phenylmethoxybutanedioic acid Chemical compound OC(=O)[C@@H](N)[C@@H](C(O)=O)OCC1=CC=CC=C1 BYOBCYXURWDEDS-IUCAKERBSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 101000866287 Homo sapiens Excitatory amino acid transporter 2 Proteins 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101000866302 Homo sapiens Excitatory amino acid transporter 3 Proteins 0.000 description 4
- ODORRXRVQKCOTD-SJORKVTESA-N [(2s,3r)-3-(phenylmethoxymethyl)oxiran-2-yl]methyl n-benzoylcarbamate Chemical compound C([C@H]1[C@H](O1)COCC=1C=CC=CC=1)OC(=O)NC(=O)C1=CC=CC=C1 ODORRXRVQKCOTD-SJORKVTESA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 150000001615 biotins Chemical class 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 150000002009 diols Chemical class 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- YYLQUHNPNCGKJQ-LWMBPPNESA-N (3S)-3-hydroxy-L-aspartic acid Chemical compound OC(=O)[C@@H](N)[C@H](O)C(O)=O YYLQUHNPNCGKJQ-LWMBPPNESA-N 0.000 description 3
- LNWXALCHPJANMJ-UHFFFAOYSA-N 1-(bromomethyl)-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(CBr)=C1 LNWXALCHPJANMJ-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100031562 Excitatory amino acid transporter 2 Human genes 0.000 description 3
- 239000003810 Jones reagent Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- LURYMYITPCOQAU-UHFFFAOYSA-N benzoyl isocyanate Chemical compound O=C=NC(=O)C1=CC=CC=C1 LURYMYITPCOQAU-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- GEOXIEOGBKDPPZ-UHFFFAOYSA-N butoxy-tert-butyl-dimethylsilane Chemical compound CCCCO[Si](C)(C)C(C)(C)C GEOXIEOGBKDPPZ-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 102000047064 human SLC1A1 Human genes 0.000 description 3
- 102000055746 human SLC1A2 Human genes 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000005556 structure-activity relationship Methods 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical class N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GZOVEPYOCJWRFC-NUNKFHFFSA-N (1r,2s)-2-[(s)-amino(carboxy)methyl]cyclopropane-1-carboxylic acid Chemical compound OC(=O)[C@@H](N)[C@H]1C[C@H]1C(O)=O GZOVEPYOCJWRFC-NUNKFHFFSA-N 0.000 description 2
- WHUUTDBJXJRKMK-SBRSOFCMSA-N (2S)-2-amino(214C)pentanedioic acid Chemical compound N[14C@@H](CCC(=O)O)C(=O)O WHUUTDBJXJRKMK-SBRSOFCMSA-N 0.000 description 2
- BYOBCYXURWDEDS-IENPIDJESA-N (2s)-2-amino-3-phenylmethoxybutanedioic acid Chemical class OC(=O)[C@@H](N)C(C(O)=O)OCC1=CC=CC=C1 BYOBCYXURWDEDS-IENPIDJESA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical group O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102000018899 Glutamate Receptors Human genes 0.000 description 2
- 108010027915 Glutamate Receptors Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- QSJFDMRMBSQMBX-IAGOWNOFSA-N [(4r,5s)-2-oxo-5-(phenylmethoxymethyl)-1,3-oxazolidin-4-yl]methyl benzoate Chemical compound C([C@H]1OC(=O)N[C@@H]1COC(=O)C=1C=CC=CC=1)OCC1=CC=CC=C1 QSJFDMRMBSQMBX-IAGOWNOFSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- JMTPHEUBVRBXKP-NEPJUHHUSA-N methyl (2s,3r)-4-[tert-butyl(dimethyl)silyl]oxy-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound CC(C)(C)[Si](C)(C)OC[C@H]([C@H](O)C(=O)OC)NC(=O)OC(C)(C)C JMTPHEUBVRBXKP-NEPJUHHUSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 210000003568 synaptosome Anatomy 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- DKTMDBQDSYQUEV-LEJLMFORSA-N (2,3,4,5,6-pentafluorophenyl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1OC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 DKTMDBQDSYQUEV-LEJLMFORSA-N 0.000 description 1
- NRSBQSJHFYZIPH-IUYQGCFVSA-N (2r,4s)-4-carboxypyrrolidin-1-ium-2-carboxylate Chemical compound OC(=O)[C@@H]1CN[C@@H](C(O)=O)C1 NRSBQSJHFYZIPH-IUYQGCFVSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- RRLCUHSIABCHRW-UHFFFAOYSA-N 3-(bromomethyl)aniline Chemical compound NC1=CC=CC(CBr)=C1 RRLCUHSIABCHRW-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- GEVGRLPYQJTKKS-UHFFFAOYSA-N 3-(phenylmethoxycarbonylamino)propanoic acid Chemical compound OC(=O)CCNC(=O)OCC1=CC=CC=C1 GEVGRLPYQJTKKS-UHFFFAOYSA-N 0.000 description 1
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-M 4-nitrobenzoate Chemical compound [O-]C(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 125000006549 C4-C10 aryl group Chemical group 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 108010000720 Excitatory Amino Acid Transporter 2 Proteins 0.000 description 1
- 102100031560 Excitatory amino acid transporter 3 Human genes 0.000 description 1
- 208000036187 Genetic neurodegenerative disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- GZOVEPYOCJWRFC-UHFFFAOYSA-N L-CCG-IV Natural products OC(=O)C(N)C1CC1C(O)=O GZOVEPYOCJWRFC-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108010084810 Neurotransmitter Transport Proteins Proteins 0.000 description 1
- 102000005665 Neurotransmitter Transport Proteins Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- KSQBAPLQXNCSOC-WDEREUQCSA-N [(2s,3r)-3-(phenylmethoxymethyl)oxiran-2-yl]methanol Chemical compound OC[C@@H]1O[C@@H]1COCC1=CC=CC=C1 KSQBAPLQXNCSOC-WDEREUQCSA-N 0.000 description 1
- KFDLHDGFDLHFRW-UHFFFAOYSA-N [O-][N+](Br)=O Chemical compound [O-][N+](Br)=O KFDLHDGFDLHFRW-UHFFFAOYSA-N 0.000 description 1
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- ZUDYPQRUOYEARG-UHFFFAOYSA-L barium(2+);dihydroxide;octahydrate Chemical compound O.O.O.O.O.O.O.O.[OH-].[OH-].[Ba+2] ZUDYPQRUOYEARG-UHFFFAOYSA-L 0.000 description 1
- TWVMOBWHILUBSS-UHFFFAOYSA-N benzoylcarbamic acid Chemical compound OC(=O)NC(=O)C1=CC=CC=C1 TWVMOBWHILUBSS-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CAKNZLNLUKXNCC-UHFFFAOYSA-N carbamoyl benzoate Chemical compound NC(=O)OC(=O)C1=CC=CC=C1 CAKNZLNLUKXNCC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- JQPDCKOQOOQUSC-OOZYFLPDSA-N dihydrokainic acid Chemical compound CC(C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O JQPDCKOQOOQUSC-OOZYFLPDSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000009540 excitatory neurotransmission Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 208000030309 inherited neurodegenerative disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- GIZSHQYTTBQKOQ-UHFFFAOYSA-N threo-Syringoylglycerol Chemical compound COC1=CC(C(O)C(O)CO)=CC(OC)=C1O GIZSHQYTTBQKOQ-UHFFFAOYSA-N 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/29—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
いくつかの遺伝的な神経変性疾患においては、患者の脳の一部にナトリウム依存性グルタミン酸取り込み活性の低下が報告されている(Rothstein, J. D. et al., N. Eng. J. Med 326, 1464-1468, 1992)。このため、グルタミン酸トランスポーターの機能の発現と阻害がこれらの疾患との関連で注目されている。
このような状況に鑑み、グルタミン酸トランスポーターとてんかん・ハンチントン氏病・筋萎縮性側索硬化症(ALS)・アルツハイマー病などの神経障害などの神経変性疾患との関連の究明のためには、種々のグルタミン酸トランスポーター阻害剤、とりわけブロッカーとして作用する阻害剤の開発が要望されている。
スキーム1
式(1)の化合物のあるものは、グルタミン酸トランスポーター蛋白の単離および/または精製のためのアフィニティーカラムのリガンドとして使用できる。アフィニティーカラムの調製のためには、公知の方法を用いることができる。(カップリング反応一般については、Amersham Pharmacia Biotechから出版されている、アフィニティークロマトグラフィーハンドブック:原理と方法、を参照;ビオチン誘導体の反応については、D. Savage, G. Matton, S. Desai, G. Nielander, S. Morgensen, E. Conklin, Avidin-Biotin Chemistry: A handbook, Pierce Chemical Company (Rockford, USA), 1992を参照)。
目的蛋白を含有する可能性のある液体試料を、上記のとおり調製したカラムに導入できる。液流を停止させて所定時間、例えば約30分間カラムをインキュベートする。蛋白は溶出バッファー(例えば、0.1 M HCl, pH 2.2)で溶出する。必要なら、蛋白溶液を脱塩カラムにとおして塩を除去する。
スキーム2
市販の(2S,3R)-[3-(ベンジルオキシメチル)オキシラニル]メタノール p-ニトロ安息香酸エステル (5.0 g , 14.6 mmol)のTHF溶液 (20 mL)に1N 水酸化ナトリウム水溶液(17.5 mL, 17.5 mmol)を加えて、0℃で1時間撹拌した。反応溶液をエーテルで抽出し、有機層を水洗後、硫酸マグネシウムで乾燥させた。溶媒を留去して油状のアルコール体を得た。これをTHF(20 mL)に溶解し、室温にてベンゾイルイソシアナート (2.57g, 17.5 mmol)のTHF溶液を加えた。反応溶液を室温で30分間撹拌し、飽和塩化アンモニウム水溶液を加えて反応を終結させた。エーテルで抽出後、有機層を硫酸マグネシウムで乾燥させた。溶媒を留去し得られたをシリカゲルカラムクロマトグラフィーにて精製し(エーテル / ヘキサン = 3 / 1)、標題化合物5.8 g (>100%)を得た。少量の不純物(ベンズアミド)を含むが、次の反応にはこれ以上の精製はせずに用いた。分析用サンプルとして一部を再結晶(エーテル/ヘキサン)にて精製した。
mp 79-81 °C; [α]D -22.9° (c 0.80, CHCl3); 1H NMR (CDCl3, 400 MHz); δ3.31 (m 2 H), 3.64 (dd, 1 H, J = 6.0, 11.5 Hz), 3.73 (dd, 1 H, J = 4.3, 11.5 Hz), 4.15 (dd, 1 H, J = 7.0, 12.0 Hz), 4.54 (dd, 1 H, J = 3.5, 12.0 Hz), 4.54 (d, 1 H, J = 12.0 Hz), 4.61 (d, 1 H, J = 12.0 Hz), 7.30 (m, 1 H), 7.35 (m, 4 H), 7.48 (ddd, 2H, J = 1.0, 7.5, 7.8 Hz), 7.59 (tt, 1 H, J = 1.0, 7.5 Hz), 7.83 (ddd, 2 H, J = 1.0, 1.0, 7.8 Hz), 8.33 (s, 1 H).
(4R,1'S)-4-(2-ベンジルオキシ-1-ベンゾイルオキシエチル)-オキサゾリジン-2-オン (3a)
(4R,5S)-4-ベンゾイルオキシメチル-5-ベンジルオキシメチル-オキサゾリジン-2-オン (3b)
ベンゾイルカルバメート(2) 5.8 gのアセトニトリル溶液(100 mL)に炭酸カリウム (4.04 g, 29.2 mmol)とヨウ化テトラブチルアンモニウム (800 mg, 2.2 mmol)を加えて、室温で18時間撹拌した。反応溶液に飽和塩化アンモニウムを加えて反応を終結させた。エーテルで抽出後、有機層を硫酸マグネシウムで乾燥させた。溶媒を留去し得られた残査をシリカゲルカラムクロマトグラフィーにて精製し(エーテル / ヘキサン = 2 / 1)、標題化合物の混合物4.87 g (3段階 98%)を得た。
3a: mp 85-87 °C; [α]D +43.6° (c 0.55, CHCl3); 1H NMR (CDCl3, 400 MHz); δ3.68 (d, 2 H, J = 5.0 Hz), 4.11 (ddd, 1 H, J =, 4.5, 5.0, 5.5 Hz), 4.27 (dd, 1 H, J = 5.5, 11.5 Hz), 4.44 (dd, 1 H, J = 4.5, 11.5 Hz), 4.57 (dt, 1 H, J = 5.0, 5.0 Hz), 4.58 (d, 1 H, J = 11.5 Hz), 4.61 (d, 1 H, J = 11.5 Hz), 6.08 (br s, 1 H), 7.33 (m, 5 H), 7.43 (ddd, 2H, J = 1.0, 7.5, 7.8 Hz), 7.57 (tt, 1 H, J = 1.0, 7.5 Hz), 8.00 (ddd, 2 H, J = 1.0, 1.0, 7.8 Hz).
3b: mp 116-117 °C; [α]D -52.6°(c 0.86, CHCl3); 1H NMR (CDCl3, 400 MHz); δ3.75 (dd, 1 H, J = 4.5, 10.5 Hz), 3.83 (dd, 1 H, J = 3.8, 10.5 Hz), 4.24 (dd, 1 H, J = 4.8, 8.8 Hz), 4.29 (ddd, 1 H, J = 3.5, 4.8, 8.5 Hz), 4.49 (d, 1 H, J = 8.5 Hz), 4.51 (d, 1 H, J = 8.5 Hz), 4.54 (d, 1 H, J = 8.8 Hz), 5.16 (ddd, 1 H, J = 3.5, 3.8, 8.5 Hz), 5.98 (s, 1 H), 7.29 (m, 5 H), 7.44 (m, 2 H), 7.58 (tt, 1 H, J = 1.5, 7.5 Hz), 8.03 (m, 2 H).
(2R,3S)-4-ベンジルオキシ-2-N-tert-ブトキシカルボニルアミノ-1,3-ブタンジオール (4)
シクロカルバメート(3) (4.05 g, 11.9 mmol)のエタノール溶液 (100 mL)に水酸化バリウム(8水塩)(11.3 g, 35.7 mmol)と水 (100 mL)を加え、縣濁液を80℃で18時間撹拌した。氷冷後10%希硫酸でpHを3に調整した。沈殿物をセライト濾去後、濾液を濃縮し、ジ-t-ブチル-ジカルボナート (5.5 mL, 23.8 mmol)、1,4-ジオキサン (100 mL)を加え、1 N水酸化ナトリウムで溶液のpHを9に調整した。反応混合物を室温にて18時間撹拌し、1 N塩酸で中和後、酢酸エチルで抽出し、有機層を硫酸マグネシウムで乾燥させた。溶媒を留去し得られた残査をシリカゲルカラムクロマトグラフィーにて精製し(エーテル / ヘキサン = 3 / 1)、標題化合物3.06g (2段階83%)を得た。
油状; [α]D +3.1° (c 0.87, CHCl3); 1H NMR (CDCl3, 400 MHz); δ1.37 (s, 9 H), 2.88 (br s, 1 H), 3.12 (s, 1 H), 3.46 (dd, 1 H, J = 7.5, 9.5 Hz), 3.53 (dd, 1 H, J = 4.5, 9.5 Hz), 3.66 (m, 1 H), 3.69 (m, 1 H), 3.79 (m, 1 H), 4.07 (s, 1 H), 4.50 (s, 2 H), 5.26 (d, 1 H, J = 7.5 Hz), 7.30 (m, 5 H)
(2R,3S)-4-ベンジルオキシ-2-N-tert-ブトキシカルボニルアミノ-1,3-ビス(tert-ブチルジメチルシリルオキシ)-ブタン (5)
ジオール(4) (2.0 g, 6.4 mmol)の 塩化メチレン溶液 (100 mL)にトリフルオロメタンスルホン酸 t-ブチルジメチルシリル (4.4 mL, 19 mmol)と2,6-ルチジン (3.0 mL)を氷冷下で加えて30分撹拌した。飽和塩化アンモニウム水溶液を加えて反応を終結させ、エーテルで抽出し、有機層を1 N塩酸、飽和塩化ナトリウム水溶液で洗い、硫酸マグネシウムで乾燥させた。溶媒を留去し得られた残査をシリカゲルカラムクロマトグラフィーにて精製し(エーテル / ヘキサン = 1 / 3)、標題化合物2.96 g (86%)とモノシリル体 295 mg (11%)を得た。
油状; [α]D -7.7° (c1.71, CHCl3); 1H NMR (CDCl3, 400 MHz); δ -0.01 (s, 3 H), 0.00 (s, 6 H), 0.02 (s, 3 H), 0.82 (s, 9 H), 0.83 (s, 9 H), 1.45 (s, 9 H), 3.39 (m, 3 H), 3.56 (dd, 1 H, J = 5.0, 10.0 Hz), 3.70 (m, 1 H), 4.12 (dt, 1 H, J = 1.5, 6.0 Hz), 4.44 (s, 2 H), 4.71 (d, 1 H, J = 9.0 Hz), 7.20 (m, 1 H), 7.28 (m, 4 H).
(2S,3R)-3-tert-ブトキシカルボニルアミノ-4-tert-ブチルジメチルシリルオキシ-2-ヒドロキシ酪酸 メチルエステル (6)
シリル保護体(5) 2.96 g (5.48 mmol)をメタノール(100 mL)に溶かし、パラジウム黒 200 mgを加えて水素雰囲気下で3時間撹拌した。触媒を濾去し、溶媒を留去した後、残査を塩化メチレン100 mLに溶かした。ここに、あらかじめ塩化オキザリル (952 μL, 11 mmol)とDMSO (1.17 mL, 16.4 mmol)を-78℃の塩化メチレン中で混合しておいたものを-78℃にて加えて、反応混合物を-78℃で10分、-50℃で1時間撹拌した。反応混合物にトリエチルアミン(3 mL, 22 mmol)を-50℃で加えた後、0℃まで昇温し5分撹拌した。飽和塩化アンモニウム水溶液を加えて反応を終結させ、エーテルで抽出し、有機層を1 N塩酸、飽和塩化ナトリウム水溶液で洗い、硫酸マグネシウムで乾燥させた。溶媒を留去し得られた残査をアセトン50 mLに溶かして0℃でJones試薬を溶液が褐色になるまで加えた。2-プロパノールを加えて反応を終結させ、エーテルで抽出した。有機層にジアゾメタンを加えてメチルエステル化し、溶液を硫酸マグネシウムで乾燥させた。溶媒を留去し、得られた残査をTHF 100 mLに溶かし、フッ化テトラn-ブチルアンモニウムのTHF溶液 (1 N, 11 mL)を加えた。酢酸エチルを加えて抽出し、有機層を5% クエン酸水溶液で洗った。有機層を硫酸マグネシウムで乾燥し、溶媒を留去して得られたラクトンとジオールの混合物をメタノールに溶かして、触媒量の酸性樹脂(amberlyst 15E)を加えて16時間撹拌した。触媒を濾去し、溶媒を留去して得られた残査をDMFに溶かし、塩化t-ブチルジメチルシリル (828 mg, 5.5 mmol)とイミダゾール (748 mg, 11 mmol)を加えて室温で3時間撹拌した。メタノールを加えて反応を終結させ、エーテルで抽出し、有機層を1 N塩酸、飽和塩化ナトリウム水溶液で洗い、硫酸マグネシウムで乾燥させた。溶媒を留去し得られた残査をシリカゲルカラムクロマトグラフィーにて精製し(エーテル / ヘキサン = 1 / 3)、標題化合物1.25 g (7段階63%)を得た。
油状; [α]D+10.7° (c1.50, CHCl3); 1H NMR (CDCl3, 400 MHz); δ0.03 (s, 6 H), 0.90 (s, 9 H), 1.44 (s, 9 H), 3.27 (d, 1 H, J = 4.0 Hz), 3.64 (dd, 1 H, J = 7.5 Hz, 9.5 Hz), 3.73 (dd, 1 H, J = 5.0, 9.5 Hz), 3.79 (s, 3 H), 4.09 (m, 1 H), 4.46 (m, 1 H), 4.87 (d, 1 H, J = 9.0 Hz).
(2S,3R)-3-N-tert-ブトキシカルボニルアミノ-4-tert-ブチルジメチルシリルオキシ-2-(3-ニトロベンジル)オキシ酪酸 メチルエステル (7)
2-OH体(6) (700 mg, 1.93 mmol)のDMF溶液5mLに-20℃で水素化ナトリウム (116 mg, 2.90 mmol), ヨウ化テトラn-ブチルアンモニウム (213 mmol, 0.60 mmol)を加え、更に臭化 3-ニトロベンジル (625 mg, 2.90 mmol)を加えて、-20℃で30分、0℃で30分撹拌した。5%クエン酸水溶液を加えて反応を終結させ、エーテルで抽出し、有機層を硫酸マグネシウムで乾燥させた。溶媒を留去し得られた残査をシリカゲルカラムクロマトグラフィーにて精製し(エーテル / ヘキサン = 1 / 3)、標題化合物759 mg (79 %)を得た。
油状; [α]D -8.7° (c 1.94, CHCl3); 1H NMR (CDCl3, 400 MHz); δ0.03 (s, 3 H), 0.06 (s, 3 H), 0.86 (s, 9 H), 1.40 (s, 9 H), 3.57 (dd, 1 H, J = 9.5, 9.5 Hz), 3.69 (dd, 1 H, J = 5.0, 9.5 Hz), 3.77 (s, 3 H), 4.18 (m, 1 H), 4.39 (d, 1 H, J = 2.0 Hz), 4.50 (d, 1 H, J = 12.0 Hz), 4.86 (d, 1 H, J = 10.0 Hz), 4.88 (d, 1 H, J = 12.0 Hz), 7.53 (dd, 1 H, J = 8.0, 8.0 Hz), 7.71 (d, 1 H, J = 8.0 Hz), 8.16 (m, 1 H), 8.22 (s, 1 H).
(2S,3R)-2-[3-(3-N-ベンジルオキシカルボニルアミノプロピオニルアミノ)ベンジルオキシ]-3-N-tert-ブトキシカルボニルアミノ-4-tert-ブチルジメチルシリルオキシ酪酸 メチルエステル (8)
ニトロベンジル体(7) (759 mg, 1.52 mmol)のメタノール溶液 30 mLに触媒量のパラジウム-炭素(10%)を加えて、水素雰囲気下で3時間撹拌した。触媒を濾去し、濾液を減圧濃縮した。残査を塩化メチレン50 mLに溶かし、N-ベンジルオキシカルボニル-β-アラニン (439 mg, 2 mmol), 1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩 (406 mg, 2 mmol)を加えて室温で30分撹拌した。エーテルと水を加えて抽出し、有機層を5% クエン酸水溶液、水、飽和炭酸水素ナトリウム水溶液、水で順次洗浄した。有機層を硫酸マグネシウムで乾燥し、溶媒を留去して得られた残査をシリカゲルカラムクロマトグラフィーにて精製し(エーテル / ヘキサン = 3 / 1)、標題化合物956 mg (2段階 94%)を得た。
油状, [α]D -5.3°(c1.68, CHCl3); 1H NMR (CDCl3, 400 MHz); δ0.03 (s, 3 H), 0.06 (s, 3 H), 0.89 (s, 9 H), 1.40 (s, 9 H), 2.58 (m, 2 H), 3.54 (m, 3 H), 3.64 (dd, 1 H, J = 5.0, 9.5 Hz), 3.74 (s, 3 H), 4.13 (m, 1 H), 4.32 (br s, 1 H), 4.36 (d, 1 H, J = 11.5 Hz), 4.69 (d, 1 H, J = 11.5 Hz), 4.98 (d, 1 H, J = 10.0 Hz), 5.08 (m, 2 H), 5.66 (br s, 1 H), 7.08 (d, 1 H, J = 7.0 Hz), 7.30 (m, 6 H), 7.48 (m, 2 H), 7.96 (s, 1 H).
(2S,3S)-3-[3-(3-N-ベンジルオキシカルボニルアミノプロピオニルアミノ)ベンジルオキシ]-2-N-tert-ブトキシカルボニル-アスパラギン酸 δ-メチルエステル (9)
化合物 8 (777 mg, 1.15 mmol)のメタノール溶液 10mLに触媒量のDL-カンファースルホン酸を加えて5時間撹拌した。エーテルと水を加えて抽出し、有機層を硫酸マグネシウムで乾燥させた。溶媒を留去し、得られた残査をアセトン5 mLに溶かして0℃でJones試薬を溶液の褐色が消えなくなるまで加えた。2-プロパノールを加えて反応を終結させ、エーテルで抽出した。飽和炭酸水素ナトリウム水溶液で水層に抽出後、水層を2 N塩酸でpH2とし、酢酸エチルで再度有機層へ抽出した。有機層を硫酸マグネシウムで乾燥し、溶媒を留去して得られた残査をシリカゲルカラムクロマトグラフィーにて精製し(メタノール / クロロホルム = 1 / 19)、標題化合物210 mg (2段階 32%)を得た。
油状; [α]D -52.5° (c0.46, CHCl3); 1H NMR (CDCl3, 400 MHz); δ1.40 (s, 9 H), 2.53 (m, 2 H), 3.48 (m, 2 H), 3.77 (s, 3 H), 4.29 (d, 1 H, J = 12.5 Hz), 4.45 (d, 1 H, J = 2.5 Hz), 4.81 (m, 2 H), 5.07 (s, 2 H), 5.48 (d, 1 H, J = 9.5 Hz), 5.83 (m, 1 H), 6.96 (d, 1 H, J = 7.0 Hz), 7.17-7.36 (m, 8 H), 8.44 (br s, 1 H).
(2S,3S)-3-[3-(3-アミノプロピオニルアミノ)ベンジルオキシ]アスパラギン酸 (AA-TBOA)
化合物9 (190 mg, 0.33 mmol)のメタノール溶液1 mLに1 N水酸化ナトリウム水溶液1.5 mLを加えて氷零下で1時間、室温で16時間撹拌した。2 N塩酸1mLを加えた後酢酸エチルで抽出し、有機層を飽和塩化ナトリウム水溶液で洗浄し、硫酸マグネシウムで乾燥させた。溶媒を留去して得られた残査をメタノール(5 mL)に溶かして、触媒量の塩酸とパラジウム黒を加えて水素雰囲気下で3時間撹拌した。触媒を濾去し、濾液を濃縮して得られた残査を塩化メチレン2 mLに溶かして、トリフルオロ酢酸1 mLを加えて15分撹拌した。溶媒を留去し、残査をDowex 50 x 100のカラムクロマトグラフィーに付し、水で洗浄後、1 Nアンモニア水で溶出した。凍結乾燥を繰り返し、標題化合物 (97 mg, 91%)を得た。
アモルファス;[α]D -25.0° (c 0.88, H2O); 1H NMR (D2O, 400 MHz); δ2.74 (t, 2 H, J = 6.5 Hz), 3.18 (t, 2 H, J = 6.5 Hz), 3.69 (s, 1 H), 4.24 (s, 1 H), 4.42 (d, 1 H, J = 12.0 Hz), 4.71 (d, 1 H, J = 12.0 Hz), 7.22 (d, 1 H, J = 7.0 Hz), 7.36 (d, 1 H, J = 7.0 Hz), 7.41 (dd, J = 7.0 Hz, 7.5 Hz), 7.50 (d, 1 H, J = 7.5 Hz).
(2S,3S)-3-[3-(3-N-ビオチニルアミノプロピオニルアミノ)ベンジルオキシ]-2-N-tert-ブトキシカルボニル-アスパラギン酸 δ-メチルエステル (10)
化合物 8 (107 mg, 0.20 mmol)のメタノール溶液 5 mLに触媒量のパラジウム-炭素(10%)を加え、水素雰囲気下で3時間撹拌した。触媒を濾去し、濾液を濃縮して得られた残査を塩化メチレン2 mLに溶かして、ビオチン ペンタフルオロフェニルエステル (91 mg, 0.22 mmol), トリエチルアミン (30 μL, 0.22 mmol)を加えて30分室温で撹拌した。反応液をエーテルで希釈し、1 N塩酸、水で洗浄した。有機層を硫酸マグネシウムで乾燥させた。溶媒を留去して得られた残査をシリカゲルカラムクロマトグラフィーにて精製し(メタノール / クロロホルム = 1 / 10)、標題化合物55 mg (2段階 46%)を得た。
油状;[α]D -26.8° (c 0.58, MeOH) 1H NMR (CDCl3, 400 MHz); δ1.40 (s, 9 H), 1.5-1.8 (m, 6 H), 2.26 (m, 2 H), 2.66 (m, 2 H), 2.77 (m, 3 H), 2.89 (dd, 1 H, J = 4.5, 13.0 Hz), 3.13 (m, 1 H), 3.46 (m, 1 H), 3.68 (m, 1 H), 3.75 (s, 3 H), 4.34 (m, 1 H), 4.42 (d, 1 H, J = 13.0 Hz), 4.44 (d, 1 H, J = 2.0 Hz), 4.51 (m, 1 H), 4.80 (dd, 1 H, J = 2.0, 9.5 Hz), 4.91 (d, 1 H, J = 13.0 Hz), 5.49 (d, 1 H, J = 9.5 Hz), 6.52 (m, 1 H), 6.61 (s, 1 H), 6.66 (s, 1 H), 6.86 (d, 1 H, J = 7.5 Hz), 7.02 (s, 1 H), 8.04 (d, 1 H, J = 8.0 Hz), 8.87 (s, 1 H).
(2S,3S)-3-[3-(3-N-ビオチニルアミノプロピオニルアミノ)ベンジルオキシ]アスパラギン酸 (Bio-AA-TBOA)
化合物 10 (13 mg, 0.22 mmol)のメタノール溶液1mLに1 N 水酸化ナトリウム水溶液66 μLを加えて室温で18時間撹拌した。反応液を2 N 塩酸でpH 1に調節し、酢酸エチルで抽出した。有機層を硫酸マグネシウムで乾燥し、溶媒を留去して得られた残査をクロロホルム1mLに溶かし、トリフルオロ酢酸1 mLを加えて15分撹拌した。溶媒を留去し、残査をDowex 50 x 100のカラムクロマトグラフィーに付し、水で洗浄後、1 Nアンモニア水で溶出した。凍結乾燥を繰り返し、標題化合物 7.9 mg (72%)を得た。
アモルファス;[α]D +6.1° (c 0.32, 50% DMSO-H2O); 1H NMR (D2O, 400 MHz); δ1.15 (m, 2 H), 1.32 (m, 1 H), 1.45 (m, 3 H), 2.53 (dd, 1 H, J = 4.0, 12.5 Hz), 2.54 (m, 2 H), 2.66 (dd, 1 H, J = 5.0, 12.5 Hz), 2.81 (m, 1 H), 3.44 (m, 2 H), 3.48 (d, 1 H, J = 4.5 Hz), 3.90 (dd, 1 H, J = 1.0, 2.0 Hz), 3.94 (dd, 1 H, J = 4.5, 8.0 Hz), 4.24 (m, 2 H), 4.37 (d, 1 H, J = 12 Hz), 4.60 (d, 1 H, J = 12 Hz), 7.09 (d, 1 H, J = 7.5 Hz), 7.22 (s, 1 H), 7.29 (dd, 1 H, J = 7.5, 7.5 Hz), 7.38 (d, 1 H, J = 7.5 Hz).
(2S,3R)-2-[3-(3-N-プロピオニルアミノプロピオニルアミノ)ベンジルオキシ]-3-N-tert-ブトキシカルボニルアミノ-4-tert-ブチルジメチルシリルオキシ酪酸 メチルエステル (11)
化合物8 (110 mg, 0.16 mmol)のメタノール溶液 10 mLに触媒量のパラジウム-炭素(10%)を加えて、水素雰囲気下で3時間撹拌した。触媒を濾去し、濾液を減圧濃縮した。残査を塩化メチレン10 mLに溶かし、氷零下でトリエチルアミン (45 μL, 0.32 mmol)、塩化プロピオニル (16 μL, 0.19 mmol)を加えて15分撹拌した。エーテルと水を加えて抽出し、有機層を飽和炭酸水素ナトリウム水溶液、、5% クエン酸水溶液、水で順次洗浄した。有機層を硫酸マグネシウムで乾燥し、溶媒を留去して得られた残査をシリカゲルカラムクロマトグラフィーにて精製し(エーテル / ヘキサン = 3 / 1)、標記化合物 75 mg (2段階 79%)を得た。
油状; 1H NMR (CDCl3, 400 MHz); δ0.03 (s, 3 H), 0.05 (s, 3 H), 0.87 (s, 9 H), 1.12 (t, 3 H, J = 7.5 Hz), 1.40 (s, 9 H), 2.19 (q, 2 H, J = 7.5 Hz), 2.62 (t, 2 H, J = 5.5 Hz), 3.58 (m, 4 H), 3.75 (s, 3 H), 4.11 (m, 1 H), 4.32 (d, 1 H, J = 1.5 Hz), 4.38 (d, 1 H, J = 11.5 Hz), 4.73 (d, 1 H, J = 11.5 Hz), 4.98 (d, 1 H, J = 9.5 Hz), 6.44 (t, 1 H, J = 5.5 Hz), 7.09 (d, 1 H, J = 7.5 Hz), 7.28 (m, 1 H), 7.51 (m, 2 H), 8.38 (s, 1 H).
(2S,3S)-3-[3-(3-N-プロピオニルアミノプロピオニルアミノ)ベンジルオキシ]アスパラギン酸 (Pr-AA-TBOA)
化合物 11 (57 mg, 0.096 mmol)のメタノール溶液 10mLに触媒量のDL-カンファースルホン酸を加えて3時間撹拌した。エーテルと水を加えて抽出し、有機層を硫酸マグネシウムで乾燥させた。溶媒を留去し、得られた残査をアセトン5 mLに溶かして0℃でJones試薬を溶液の褐色が消えなくなるまで加えた。2-プロパノールを加えて反応を終結させ、エーテルで抽出した。飽和炭酸水素ナトリウム水溶液で水層に抽出後、水層を2 N塩酸でpH2とし、酢酸エチルで再度有機層へ抽出した。有機層を硫酸マグネシウムで乾燥し、溶媒を留去して得られた残査をメタノール1mLに溶かし、1 N 水酸化ナトリウム水溶液1 mLを加えて室温で18時間撹拌した。反応液を2 N 塩酸でpH 1に調節し、酢酸エチルで抽出した。有機層を硫酸マグネシウムで乾燥し、溶媒を留去して得られた残査をクロロホルム1mLに溶かし、トリフルオロ酢酸1 mLを加えて15分撹拌した。溶媒を留去し、残査をDowex 50 x 100のカラムクロマトグラフィーに付し、水で洗浄後、1 Nアンモニア水で溶出した。凍結乾燥を繰り返し、標題化合物 14 mg (5 steps , 39%)を得た。
アモルファス;[α]D -17.3 ° (c 0.71, H2O); 1H NMR (D2O, 400 MHz); δ1.11 (t, 3 H, J = 7.5 Hz), 2.27 (q, 2 H, J = 7.5 Hz), 2.66 (t, 2 H, J = 6.5 Hz), 3.57 (t, 2 H, J = 6.5 Hz), 3.68 (s, 1 H), 4.24 (s, 1 H), 4.44 (d, 1 H, J = 12.0 Hz), 4.72 (d, 1 H, J = 12.0 Hz), 7.24 (d, 1 H, J = 7.5 Hz), 7.32 (s, 1 H), 7.43 (t, 1 H, J = 7.5 Hz), 7.51 (d, 1 H, J = 7.5 Hz).
β-アラニンを含まない化合物についてもScheme 3に従い、同様の方法でA-TBOA, Bio-A-TBOA, Pr-A-TBOA, Piv-A-TBOA, PhAcA-TBOA, cHexcA-TBOA, BzA-TBOA, o-MeO-BzA-TBOA, m-MeO-BzA-TBOA, p-MeO-BzA-TBOA, diMeO-BzA-TBOA, tBu-BzA-TBOA, Ph-BzA-TBOA, CN-BzA-TBOA, NO2-BzA-TBOA, F-BzA-TBOA, OCF3-BzA-TBOA, CF3-BzA-TBOA, OHex-BzA-TBOA, Hep-BzA-TBOA を合成した。
スキーム3
アモルファス;1H NMR (D2O, 400 MHz); δ3.86 (d, 1 H, J = 2.0 Hz), 4.19 (d, 1 H, J = 2.0 Hz), 4.26 (d, 1 H, J = 11.6 Hz), 4.52 (d, 1 H, J = 11.6 Hz), 6.70 (m, 3 H), 7.10 (t, 1 H, J = 7.6 Hz).
(2S,3S)-3-[3-(N-ビオチニルアミノ)ベンジルオキシ]アスパラギン酸 (Bio-A-TBOA)
アモルファス;[α]D +31.1° (c 0.35, H2O); δ1.53 (m, 2 H), 1.68 (m, 1 H), 1.79 (m, 3 H), 2.49 (t, 2 H, J = 7.8 Hz), 2.82 (d, 1 H, J = 13.0 Hz), 3.04 (dd, 1 H, J = 5.0, 13.0 Hz), 3.40 (m, 1 H), 3.70 (s, 1 H), 4.26 (s, 1 H), 4.44 (d, 1 H, J = 12.0 Hz), 4.47 (dd, 1 H, J = 4.5, 8.0 Hz), 4.67 (dd, 1 H, J = 5.0, 7.5 Hz), 4.73 (d, 1 H, J = 12.0 Hz), 7.25 (d, 1 H, J = 7.5 Hz), 7.32 (s, 1 H), 7.44 (t, 1 H, J = 7.5 Hz), 7.53 (d, 1 H, J = 7.5 Hz).
(2S,3S)-3-[3-(N-プロピオニルアミノ)ベンジルオキシ]アスパラギン酸 (Pr-A-TBOA)
アモルファス;1H NMR (D2O, 400 MHz); δ1.07 (t, 3 H, J = 7.5 Hz), 2.30 (q, 2 H, J = 7.5 Hz), 3.70 (s, 1 H), 4.14 (s, 1 H), 4.31 (d, 1 H, J = 12.0 Hz), 4.58 (d, 1 H, J = 12.0 Hz), 7.08 (d, 1 H, J = 7.5 Hz), 7.13 (s, 1 H), 7.28 (d, 1 H, J = 7.5 Hz), 7.34 (d, 1 H, J = 8.0 Hz).
(2S,3S)-3-[3-(N-ピバロイルアミノ)ベンジルオキシ]アスパラギン酸 (Piv-A-TBOA)
アモルファス;[α]D -27.7° (c 0.31, H2O); 1H NMR (D2O, 400 MHz); δ1.20 (s, 9 H), 3.86 (dd, 1 H, J = 2.0, 2.5 Hz), 4.20 (dd, 1 H, J = 2.0, 2.5 Hz), 4.34 (d, 1 H, J = 12 Hz), 4.57 (d, 1 H, J = 12 Hz), 7.10 (d, 1 H, J = 7.0 Hz), 7.17 (s, 1 H), 7.25 (m, 2 H)
(2S,3S)-3-[3-(N-フェニルアセチルアミノ)ベンジルオキシ]アスパラギン酸 (PhAcA-TBOA)
1H-NMR (DMSO-d6, D2O) δ:3.61 (s, 2 H), 3.89 (d, 1 H, J = 8.5 Hz), 4.16 (d, 1 H, J = 8.5 Hz), 4.43 (d, 1 H, J = 11.0 Hz), 4.76 (d, 1 H, J = 11.0 Hz), 7.14 (d, 1 H, J = 7.0 Hz), 7.20-7.35 (m, 6 H), 7.53 (d, 1 H, J = 7.0 Hz), 7.55 (s, 1 H).
(2S,3S)-3-[3-(N-シクロヘキシルカルボニルアミノ)ベンジルオキシ]アスパラギン酸 (cHexcA-TBOA)
1H-NMR (DMSO-d6, D2O) δ: 1.10-1.42 (m, 6 H), 1.73 (m, 4 H), 2.29 (m, 1 H), 4.27 (d, 1 H, J = 3.5 Hz), 4.46 (d, 1 H, J = 12.0 Hz), 4.49 (d, 1 H, J = 3.5 Hz), 4.72 (d, 1 H, J = 12.0 Hz), 7.03 (d, 1 H, J = 7.5 Hz), 7.26 (t, 1 H, J = 7.5 Hz), 7.46 (d, 1 H, J = 8.0 Hz), 7.55 (s, 1 H).
(2S,3S)-3-[3-(N-ベンゾイルアミノ)ベンジルオキシ]アスパラギン酸 (BzA-TBOA)
1H-NMR (CD3OD) δ: 4.46 (d, 1 H, J = 11.5 Hz), 4.59 (d, 1 H, J = 2.5 Hz), 4.72 (d, 1 H, J = 2.5 Hz), 4.82 (d, 1 H, J = 11.5 Hz), 7.14 (d, 1 H, J = 7.5 Hz), 7.34 (t, 1 H, J = 7.5 Hz), 7.50 (m, 2 H), 7.57 (m, 1 H), 7.63 (s, 1 H), 7.67 (d, 1 H, J = 7.5 Hz), 7.93 (m, 2 H).
(2S,3S)-3-[3-[N-(2-メトキシベンゾイル)アミノ]ベンジルオキシ]アスパラギン酸 (o-MeO-0BzA-TBOA)
1H-NMR (DMSO-d6, D2O) δ: 3.86 (3 H, s), 4.06 (d, 1 H, J = 4.0 Hz), 4.42 (d, 1 H, J = 4.0 Hz), 4.48 (d, 1 H, J = 11.5 Hz), 4.72 (d, 1 H, J = 11.5 Hz), 7.05 (t, 1 H, J = 7.5 Hz), 7.19 (d, 1 H, J = 7.5 Hz), 7.14 (d, 1 H, J = 7.5 Hz), 7.31 (t, 1 H, J = 7.5 Hz), 7.49 (dt, 1 H, J = 1.5, 8.0 Hz), 7.59 (s, 1 H), 7.60 (d, 1 H, J = 7.5 Hz), 7.65 (dd, 1 H, J = 1.5, 7.5 Hz).
(2S,3S)-3-[3-[N-(3-メトキシベンゾイル)アミノ]ベンジルオキシ]アスパラギン酸 (m-MeO-BzA-TBOA)
1H-NMR (DMSO-d6, D2O) δ: 3.84 (s, 3 H), 4.15 (d, 1 H, J = 4.5 Hz), 4.39 (d, 1 H, J = 4.5 Hz), 4.50 (d, 1 H, J = 9.5 Hz), 4.80 (d, 1 H, J = 9.5 Hz), 7.16 (m, 2 H), 7.33 (t, 1 H, J = 6.5 Hz), 7.44 t, 1 H, J = 6.5 Hz), 7.47 (m, 1 H), 7.53 (d, 1 H, J = 6.5 Hz), 7.67 (d, 1 H, J = 7.0 Hz), 7.74 (s, 1 H).
(2S,3S)-3-[3-[N-(4-メトキシベンゾイル)アミノ]ベンジルオキシ]アスパラギン酸 (p-MeO-BzA-TBOA)
1H-NMR (DMSO-d6, D2O) δ:3.82 (s, 3 H), 3.95 (d, 1 H, J = 7.5 Hz), 4.23 (d, 1 H, J = 7.5 Hz), 4.48 (d, 1 H, J = 11.0 Hz), 4.80 (d, 1 H, J = 11.0 Hz), 7.04 (d, 2 H, J = 9.0 Hz), 7.18 (d, 1 H, J = 7.5 Hz), 7.30 (t, 1 H, J = 7.5 Hz), 7.66 (d, 1 H, J = 7.5 Hz), 7.72 (s, 1 H), 7.94 (d, 2 H, J = 9.0 Hz).
(2S,3S)-3-[3-[N-(3,4-ジメトキシベンゾイル)アミノ]ベンジルオキシ]アスパラギン酸 (diMeO-BzA-TBOA)
1H-NMR (DMSO-d6, D2O) δ: 3.79 (s, 6 H), 4.14 (d, 1 H, J = 4.5 Hz), 4.41 (d, 1 H, J = 4.5 Hz), 4.48 (d, 1 H, J = 9.5 Hz), 4.71 (d, 1 H, J = 9.5 Hz), 7.04 (d, 1 H, J = 8.5 Hz), 7.10 (d, 1 H, J = 7.5 Hz), 7.31 (t, 1 H, J = 6.5 Hz), 7.46 (d, 1 H, J = 2.0 Hz), 7.55 (dd, 1 H, J = 2.5, 8.5 Hz), 7.58 (d, 2 H, J = 8.5 Hz).
(2S,3S)-3-[3-[N-(4-tert-ブチルベンゾイル)アミノ]ベンジルオキシ]アスパラギン酸 (tBu-BzA-TBOA)
1H-NMR (DMSO-d6, D2O) δ: 1.33 (s, 9 H), 4.05 (s, 1 H), 7.08 (d, 1 H, J = 7.0 Hz), 7.32 (t, 1 H, J = 7.5 Hz), 7.48 (s, 2 H), 7.50 (d, 2 H, J = 7.5 Hz), 7.74 (d, 2 H, J = 7.5 Hz).
(2S,3S)-3-[3-[N-(4-フェニルベンゾイル)アミノ]ベンジルオキシ]アスパラギン酸 (Ph-BzA-TBOA)
1H-NMR (DMSO-d6, D2O) δ: 3.92 (d, 1 H, J = 3.5 Hz), 4.38 (d, 1 H, J = 3.5 Hz), 4.48 (d, 1 H, J = 12.0 Hz), 4.71 (d, 1 H, J = 12.0 Hz), 7.13 (d, 1 H, J = 8.0 Hz), 7.33 (t, 1 H, J = 8.0 Hz), 7.39 (t, 1 H, J = 7.5 Hz), 7.48 (t, 2 H, J = 7.5 Hz), 7.64 (m, 2 H), 7.50 (d, 2 H, J = 8.0 Hz), 7.78 (d, 2 H, J = 8.0 Hz), 7.98 (d, 2H, J = 8.0 Hz)
(2S,3S)-3-[3-[N-(4-シアノベンゾイル)アミノ]ベンジルオキシ]アスパラギン酸 (CN-BzA-TBOA)
1H-NMR (DMSO-d6, D2O) δ: 4.30 (d, 1 H, J = 3.5 Hz), 4.52 (d, 1 H, J = 3.5 Hz), 4.54 (d, 1 H, J = 12.0 Hz), 4.79 (d, 1 H, J = 12.0 Hz), 7.16 (d, 1 H, J = 7.5 Hz), 7.37 (t, 1 H, J = 7.5 Hz), 7.64 (d, 1 H, J = 8.0 Hz), 7.71 (s, 1 H), 7.98 (d, 2 H, J = 8.5 Hz), 8.07 (d, 2 H, J = 8.5 Hz).
(2S,3S)-3-[3-[N-(4-ニトロベンゾイル)アミノ]ベンジルオキシ]アスパラギン酸 (NO2-BzA-TBOA)
1H-NMR (DMSO-d6, D2O) δ: 4.28 (d, 1 H, J = 3.5 Hz), 4.50 (d, 1 H, J = 3.5 Hz), 4.52 (d, 1 H, J = 11.5 Hz), 4.76 (d, 1 H, J = 11.5 Hz), 7.14 (d, 1 H, J = 8.0 Hz), 7.36 (t, 1 H, J = 8.0 Hz), 7.62 (d, 1 H, J = 8.0 Hz), 7.69 (s, 1 H), 8.10 (d, 2 H, J = 8.5 Hz), 8..32 (d, 2 H, J = 8.5 Hz).
(2S,3S)-3-[3-[N-(4-フルオロベンゾイル)アミノ]ベンジルオキシ]アスパラギン酸 (F-BzA-TBOA)
1H-NMR (DMSO-d6, D2O) δ: 4.30 (d, 1 H, J = 3.5 Hz), 4.52 (d, 1 H, J = 3.5 Hz), 4.53 (d, 1 H, J = 11.5 Hz), 4.77 (d, 1 H, J = 11.5 Hz), 7.12 (d, 1 H, J = 7.5 Hz), 7.33 (m, 3 H), 7.63 (d, 1 H, J = 8.0 Hz), 7.70 (s, 1 H), 7.99 (m, 2 H).
(2S,3S)-3-[3-[N-(4-トリフルオロメトキシベンゾイル)アミノ]ベンジルオキシ]アスパラギン酸 (OCF3-BzA-TBOA)
1H-NMR (DMSO-d6, D2O) δ: 4.25 (d, 1 H, J = 3.5 Hz), 4.48 (d, 1 H, J = 3.5 Hz), 4.50 (d, 1 H, J = 12.0 Hz), 4.65 (d, 1 H, J = 12.0 Hz), 7.14 (d, 1 H, J = 8.0 Hz), 7.32 (t, 1 H, J = 8.0 Hz), 7.46 (d, 2 H, J = 8.5 Hz), 7.59 (s, 1 H), 7.61 (d, 1 H, J = 8.0 Hz), 7.99 (d, 2 H, J = 8.5 Hz).
(2S,3S)-3-[3-[N-(4-トリフルオロメチルベンゾイル)アミノ]ベンジルオキシ]アスパラギン酸 (CF3-BzA-TBOA)
1H-NMR (DMSO-d6, D2O) δ: 4.28 (d, 1 H, J = 3.5 Hz), 4.51 (d, 1 H, J = 3.5 Hz), 4.53 (d, 1 H, J = 12.0 Hz), 4.77 (d, 1 H, J = 12.0 Hz), 7.14 (d, 1 H, J = 7.5 Hz), 7.36 (t, 1 H, J = 7.5 Hz), 7.63 (d, 1 H, J = 8.0 Hz), 7.70 (s, 1 H), 7.87 (d, 2 H, J = 8.5 Hz), 8.08 (d, 2 H, J = 8.5 Hz).
(2S,3S)-3-[3-[N-(4-n-ヘキシルオキシベンゾイル)アミノ]ベンジルオキシ]アスパラギン酸 (OHex-BzA-TBOA)
1H-NMR (DMSO-d6, D2O) δ: 0.81 (t, 3 H, J = 7.0 Hz), 1.24 (m, 6 H), 1.35 (m, 2 H), 3.92 (d, 1 H, J = 4.0 Hz), 3.99 (t, 2 H, J = 6.5 Hz), 4.38 (d, 1 H, J = 4.0 Hz), 4.46 (d, 1 H, J = 11.5 Hz), 4.68 (d, 1 H, J = 11.5 Hz), 6.98 (d, 2 H, J = 9.0 Hz), 7.09 (d, 1 H, d, J = 7.5 Hz), 7.30 (t, 1 H, J = 7.5 Hz), 7.57 (s, 1 H), 7.58 (d, 1 H, J = 7.5 Hz), 7.84 (d, 2 H, J = 9.0 Hz).
(2S,3S)-3-[3-[N-(4-n-へプチルベンゾイル)アミノ]ベンジルオキシ]アスパラギン酸 (Hep-BzA-TBOA)
1H-NMR (DMSO-d6, D2O) δ: 0.83 (t, 3 H, J = 6.5 Hz), 1.24 (m, 8 H), 1.56 (m, 2 H), 2.62 (t, 2 H, J = 7.5 Hz), 3.81 (d, 1 H, J = 6.5 Hz), 4.28 (d, 1 H, J = 6.5 Hz), 4.48 (d, 1 H, J = 11.0 Hz), 4.75 (d, 1 H, J = 11.0 Hz), 7.17 (d, 1 H, J = 7.5 Hz), 7.30 (m, 3 H), 7.68 (m, 2 H), 7.85 (d, 2 H, J = 7.5 Hz).
(2S,3S)-3-[3-(N-(4-(5-アミノペンチルオキシ)ベンゾイル)アミノ)ベンジルオキシ]アスパラギン酸 (A-PenO-BzA-TBOA)
1H-NMR (D2O) δ: 1.36 (tt, 2 H, J = 7.5 Hz), 1.58 (tt, 2 H, J = 7.5 Hz), 1.66 (tt, 2 H, J = 7.5 Hz), 2.86 (t, 2 H, J = 7.5 Hz), 3.94 (t, 2 H, J = 6.0 Hz), 4.30 (s, 1 H), 4.44 (d, 1 H, J = 12.0 Hz), 4.52 (s, 1 H), 4.68 (d, 1 H, J = 12.0 Hz), 6.89 (d, 2 H, J = 7.5 Hz), 7.08 (d, 1 H, J = 7.0 Hz), 7.31 (m, 3 H), 7.66 (d, 2 H, J = 7.5 Hz).
(2S,3S)-3-[3-(N-(4-(5-ビオチニルアミノペンチルオキシ)ベンゾイル)アミノ)ベンジルオキシ] アスパラギン酸 (BioA-PenO-BzA-TBOA)
1H-NMR (DMSO-d6, D2O) δ: 1.20-1.65 (m, 12 H), 1.71 (m, 2 H), 2.04 (t, 2 H J = 7.0 Hz), 2.56 (d, 1 H, J = 13.0 Hz), 2.78 (dd, 1 H, J = 4.5, 13.0 Hz), 3.05 (m, 3 H), 4.01 (t, 2 H, J = 5.5 Hz), 4.13 (m, 1 H), 4.32 (m, 2 H), 4.48 (d, 1 H, J = 11.5 Hz), 4.71 (d, 1 H, J = 11.5 Hz), 7.01 (d, 2 H, J = 8.0 Hz), 7.13 (d, 1 H, J = 7.0 Hz), 7.30 (t, 1 H, J = 7.5 Hz), 7.64 (m, 2 H), 7.89 (d, 2 H, J = 8.0 Hz).
同様の手法でpara-置換体 (p-Pr-A-TBOA)も合成した。
(2S,3S)-3-[4-(N-プロピオニルアミノ)ベンジルオキシ]アスパラギン酸 (p-Pr-A-TBOA)
アモルファス;1H NMR (50% D2O/DMSO-d6, 400 MHz); δ1.03 (t, 3 H, J = 7.5 Hz), 2.27 (q, 2 H, J = 7.5 Hz), 4.20 (s, 1 H), 4.43 (d, 1 H, J = 12.0 Hz), 4.60 (s, 1 H), 4.66 (d, 1 H, J = 12.0 Hz), 7.22 (d, 2 H, J = 7.0 Hz), 7.39 (m, 2 H).
公知の方法(Shimamoto, K. et al., Mol. Pharmacol. 53, 195-201, 1998; Bioorg. Med. Chem. Lett. 10, 2407-2410, 2000)に従い、恒常的にMDCK (Madin-Darby Canine Kidney) 細胞に発現させた、または一過性にCOS-1細胞に発現させた、ヒトEAAT2およびEAAT3において[14C]グルタミン酸の取り込み阻害作用を測定した。グルタミン酸取り込み活性は、1 μMのL-[14C]グルタミン酸と所定の濃度の試料を加えて12分間インキュベートした後細胞を溶解して、取り込まれた放射活性を液体シンチレーターにより測定した。取り込み量は化合物が無い(緩衝液のみ)場合を100%とし、ナトリウムフリー溶液での取り込みの場合を0%とした%で表示し、IC50値を求め表1に示した。
調製例 1.
CNBr-活性化セファロース (Sepharose) 4B (Amersham Biosciences) の所定量をグラスフィルター上に秤取する。1 mM HClを用いて洗浄と膨潤を繰り返えす。本発明の化合物(リガンド)をカップリング用バッファー(例えば、0.5 M NaClを含む0.1 M NaHCO3, pH 8.3)に溶解する。このリガンド溶液をゲル分散液と室温で2時間または4 ℃で一夜混合する。次に、ゲルをブロッキング剤、例えば1M エタノールアミンまたは0.2 Mグリシン, pH 8.0中に導入する。このゲルをカップリング用バッファーおよび酢酸バッファー(0.5 M NaCl, 0.1 M AcOH, pH 4)にてこの順序で洗浄して、過剰のリガンドをおよびブロッキング剤を除去する。ゲルは4-8℃で保存する。
所定量のECH セファロース(Sepharose) 4B (Amersham Biosciences)を、グラスフィルター上に秤取し、0.5 M NaClで洗浄する。本発明の化合物(リガンド)を水に溶解し、このpHを4.5に調節する。カルボジイミドの水溶液を調製し、そのpHを4.5に調節する。膨潤したゲル、リガンド溶液およびカルボジイミド溶液を混合して、室温で一夜反応させる。過剰のリガンド、尿素誘導体および残存リガンドを洗浄して除去する。ゲルは4-8℃で保存する。
固定化したアビジンまたはストレプトアビジンのスラリーを、カラムに注入する。充填したカラムは、5倍量の結合バッファー(例えば、PBS)で洗浄して平衡化させる。本発明のビオチン化化合物をカラムに導入し、カラムを30分間静置する。カラムを10倍量の結合バッファーで洗浄する。
Claims (18)
- Rが水酸基またはチオール基で置換されてもよい直鎖または分岐低級脂肪族アシル基、環状脂肪族アシル基、芳香環上に置換基を有してもよい芳香族アシル基、または水酸基もしくはチオール基を含むアミノ酸類由来の基である、請求項1の化合物。
- Rがアセチル基、プロピオニル基、n-ブタノイル基、sec-ブタノイル基、n-ペンタノイル基、ピバロイル基、フェニルアセチル基、シクロヘキシルカルボニル基、ベンゾイル基、置換ベンゾイル基、ナフトイル基、またはピリジルカルボニル基である、請求項1の化合物。
- Rがグリシル基、アラニル基、β-アラニル基、またはシステイニル基である、請求項1の化合物。
- Rがビオチニル基、またはビオチニル-β-アラニル基である、請求項1の化合物。
- Rが置換されていてもよいアルコキシ基、置換されていてもよいアルキル基、置換されていてもよいアリール基、シアノ基、ニトロ基およびハロゲン原子からなる群から選択される一または二以上の置換基で置換されたベンゾイル基である、請求項3の化合物。
- ベンゾイル基上の置換基が同位元素を含む、請求項6の化合物。
- 式(7)で表されるL−スレオ−ニトロベンジル化(2S,3R)化合物の収率が少なくとも70%である、請求項9の方法。
- 式(7)の化合物のベンゼン環上のNO2基をNHR基(基中、RはZ基を示すか、またはRは請求項1ないし5のいずれかにおいて定義した意味を示す)に変換して請求項1ないし5のいずれか1項の化合物を製造し、存在するなら保護基を全て除去する工程をさらに含む、請求項9または10の方法。
- −NHR基と反応性の官能基を有する固体担体、および式(1)のベンゼン環上の−NHR基と前記担体の反応性基との反応によって前記固定担体に結合した請求項1で定義した式(1)のL−スレオ−β−ベンジルオキシアスパラギン酸誘導体からなる、L-グルタミン酸トランスポーター蛋白に特異的に結合することができるアフィニティーカラム用リガンド。
- RがHであり、そしてL−スレオ−β−ベンジルオキシアスパラギン酸誘導体が、L−スレオ−β−ベンジルオキシアスパラギン酸のベンゼン環上の−NH2と固体担体上のカルボキシもしくはハロアルキル基との反応によって、固体担体に結合した、請求項14のリガンド。
- Rがビオチニル基であり、そしてL−スレオ−β−ベンジルオキシアスパラギン酸誘導体が、ビオチニル基と固体担体上のアビジン残基との反応により固体担体に結合している、請求項14のリガンド。
- 請求項14ないし16のいずれかで定義したアフィニティーリガンドを用意し;
L−グルタミン酸トランスポーター蛋白を含む可能性がある水溶液中の生物学的サンプルを、上記アフィニティーリガンドと接触させ;
上記アフィニティーリガンドを洗浄し;そして
上記アフィニティーリガンドからL−グルタミン酸トランスポーター蛋白を溶出する;
工程からなる、生物学的試料中のL−グルタミン酸トランスポーター蛋白を精製または同定する方法。 - 哺乳類(ヒトを除く。)に、請求項1ないし7のいずれかに定義した式(1)の化合物またはその塩の有効量および薬学的に許容される担体を含む医薬組成物を投与することからなる、哺乳類(ヒトを除く。)のL−グルタミン酸トランスポーター関連の神経変性疾患の治療方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001190022 | 2001-06-22 | ||
PCT/JP2002/006286 WO2003000698A1 (en) | 2001-06-22 | 2002-06-24 | β-BENZYLOXYASPARTATE DERIVATIVES WITH AMINO GROUP ON BENZENE RING |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005504016A JP2005504016A (ja) | 2005-02-10 |
JP2005504016A5 JP2005504016A5 (ja) | 2006-01-05 |
JP4542336B2 true JP4542336B2 (ja) | 2010-09-15 |
Family
ID=19028851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003507101A Expired - Lifetime JP4542336B2 (ja) | 2001-06-22 | 2002-06-24 | ベンゼン環上にアミノ基を有するβ−ベンジルオキシアスパラギン酸誘導体 |
Country Status (4)
Country | Link |
---|---|
US (2) | US7247652B2 (ja) |
EP (1) | EP1397370B1 (ja) |
JP (1) | JP4542336B2 (ja) |
WO (1) | WO2003000698A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1628951B1 (en) * | 2003-05-30 | 2010-05-26 | Suntory Holdings Limited | (beta)-benzyloxyaspartate derivatives with photosensitive groups |
WO2005090268A1 (en) * | 2004-03-18 | 2005-09-29 | Suntory Limited | Radiolabeled 3-[3-(benzoyl-amido)benzyloxy]aspartic acid derivative and method of producing the same |
US20070142467A1 (en) * | 2004-10-21 | 2007-06-21 | The University Of Montana | 3-alkylaryl aspartate compounds and their use for selective enhancement of synaptic transmission |
JP4008446B2 (ja) | 2004-12-27 | 2007-11-14 | サントリー株式会社 | ベンゼン環上に二置換基を有するβ−ベンジルオキシアスパラギン酸誘導体 |
WO2011104307A2 (en) * | 2010-02-25 | 2011-09-01 | Graffinity Pharmaceuticals Gmbh | Ligands for antibody purification by affinity chromatography |
CN103134893B (zh) * | 2013-01-25 | 2014-12-03 | 峨眉山天梁星制药有限公司 | 一种3-叔丁基二甲硅氧基戊二酸酐的高效液相色谱分析法 |
KR102468563B1 (ko) | 2014-10-06 | 2022-11-17 | 티이엘 매뉴팩처링 앤드 엔지니어링 오브 아메리카, 인크. | 극저온 유체 혼합물로 기판을 처리하는 시스템 및 방법 |
US10014191B2 (en) | 2014-10-06 | 2018-07-03 | Tel Fsi, Inc. | Systems and methods for treating substrates with cryogenic fluid mixtures |
US10625280B2 (en) | 2014-10-06 | 2020-04-21 | Tel Fsi, Inc. | Apparatus for spraying cryogenic fluids |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5576323A (en) * | 1993-12-03 | 1996-11-19 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
JP3936418B2 (ja) * | 1996-10-25 | 2007-06-27 | サントリー株式会社 | β−ヒドロキシアスパラギン酸誘導体 |
-
2002
- 2002-06-24 US US10/481,237 patent/US7247652B2/en not_active Expired - Lifetime
- 2002-06-24 WO PCT/JP2002/006286 patent/WO2003000698A1/en active Application Filing
- 2002-06-24 JP JP2003507101A patent/JP4542336B2/ja not_active Expired - Lifetime
- 2002-06-24 EP EP02743696.3A patent/EP1397370B1/en not_active Expired - Lifetime
-
2007
- 2007-06-14 US US11/808,970 patent/US7666906B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US7247652B2 (en) | 2007-07-24 |
JP2005504016A (ja) | 2005-02-10 |
WO2003000698A1 (en) | 2003-01-03 |
US20040242652A1 (en) | 2004-12-02 |
EP1397370A1 (en) | 2004-03-17 |
US7666906B2 (en) | 2010-02-23 |
US20070238783A1 (en) | 2007-10-11 |
EP1397370B1 (en) | 2014-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7666906B2 (en) | β-Benzyloxyaspartate derivatives with amino group on benzene ring | |
CN100369894C (zh) | 氧化氮合酶抑制剂磷酸盐 | |
JP7036792B2 (ja) | スピロ-ラクタムnmda受容体修飾因子およびその使用 | |
JPH06509332A (ja) | 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用 | |
EA015931B1 (ru) | Бензамидные производные как агонисты ер-рецепторов | |
JP2001517651A (ja) | 新しいnpy拮抗剤 | |
JPH09502448A (ja) | 心臓血管系に活性な2−アミノ−1,2,3,4−テトラヒドロナフタレン誘導体 | |
DK2940007T3 (en) | TYROSINE DERIVATIVES AND PROCEDURE FOR PREPARING TYROSINE DERIVATIVES | |
JP5311822B2 (ja) | 置換プロパンアミド誘導体及びそれを含む医薬組成物 | |
JP2014513663A (ja) | 効率的なペプチドカップリングおよびシクロペンタ[g]キナゾリン3ナトリウム塩の合成および単離でのそれらの使用 | |
US7670784B2 (en) | β-Benzyloxyaspartic acid derivatives having two substituents on their benzene rings | |
WO2021144814A1 (en) | Methods, processes and intermediates for preparing chroman compounds | |
WO1995004715A1 (fr) | Derive d'acylphenylglycine et agent preventif et curatif, concernant des maladies causees par une activite collagenase accrue, contenant un tel compose comme ingredient actif | |
DE60113406T2 (de) | N-substituierte peptidylnitrile als cystein-cathepsin-inhibitoren | |
AU708504B2 (en) | Novel heterocyclic compounds for the treatment of pain and use thereof | |
JP3936418B2 (ja) | β−ヒドロキシアスパラギン酸誘導体 | |
JPH08269008A (ja) | ディスタマイシン類似構造をもつ化合物と、それを含む抗癌剤 | |
KR850000049B1 (ko) | α-치환 우레이도 벤질 페니실린 유도체의 제조방법 | |
KR20050094452A (ko) | 사이클로프로필 베타-아미노산 유도체 | |
JPS643865B2 (ja) | ||
JPH0328438B2 (ja) | ||
JP2003518111A (ja) | 非ペプチドタキキニンレセプターアンタゴニスト | |
JPH08198820A (ja) | ジアダマンタン誘導体およびその用途 | |
JPS6121466B2 (ja) | ||
JPS6357419B2 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050607 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050607 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090305 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20090422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090501 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100324 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100528 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100625 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4542336 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130702 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |